Key result
Nebivolol and olmesartan prevented blood pressure increases (>50 mmHg in placebo) and maintained normal creatinine clearance in rats with NO synthase inhibition.
Why the study?
Does nebivolol or olmesartan prevent hypertension and chronic kidney disease in rats with chronic nitric oxide synthase inhibition?
Does nebivolol or olmesartan prevent hypertension and chronic kidney disease in rats with chronic nitric oxide synthase inhibition?
Nebivolol and olmesartan both effectively prevent hypertension and kidney injury induced by chronic nitric oxide synthase inhibition in rats, likely by reducing oxidative stress.
Answers are grounded in this paper and cite their sources.
Should not change practice; hypothesis-generating for nebivolol and olmesartan in nitric oxide-deficient hypertension and CKD models.
BACKGROUND: Nitric oxide (NO) deficiency contributes to chronic kidney disease (CKD) progression and hypertension. The β-blocker, nebivolol (N), also enhances NO production, and we studied whether N attenuates CKD and hypertension caused by chronic NO synthase inhibition (CNOSI). METHODS: Male Sprague-Dawley rats on 6 weeks of CNOSI (L-NAME, 150 mg/L drinking water) received placebo (P), N (10 mg/kg/day), olmesartan (O, 2.5 mg/kg/day) or N + O. Blood pressure (BP) and urine protein and NOx (metabolites of NO) were monitored throughout. We measured glomerular sclerosis (GS), creatinine clearance (C(Cr)) and components of the NO and oxidant pathways in the renal cortex. RESULTS: BP increased >50 mmHg in P by weeks 4-6, but no change occurred in N, O or N + O. P rats developed proteinuria and GS and C(Cr) was ∼30% of normal. In N, O and N + O, all values remained normal. In renal cortex of P, p22phox and nitrotyrosine abundance as well as H(2)O(2) levels were higher and extracellular superoxide dismutase (EC SOD) was lower versus normal kidneys. N, O and N + O normalized p22phox, H(2)O(2) and EC SOD and increased Mn SOD above normal. The cortical neuronal NO synthase (nNOS) β abundance increased in P and this was prevented by N, O and N + O. CONCLUSION: We suggest that the major benefit from both N and O is reduction in oxidative stress in the renal cortex, which may potentiate residual local NO. There was no additive benefit of N + O since each drug effectively prevented injury, but a combination may be beneficial where protection is incomplete with each drug. The increased nNOSβ protein seen early in the course of the CKD may contribute to the evolving GS.
No takes yet. Share an insight, caveat, or question.
Moningka et al. (2011) studied Chronic kidney disease and hypertension. Nebivolol, Olmesartan, or Nebivolol + Olmesartan vs. Placebo was evaluated on Blood pressure, urine protein, NOx, glomerular sclerosis, creatinine clearance, and oxidative stress markers. Nebivolol and olmesartan prevented blood pressure increases (>50 mmHg in placebo) and maintained normal creatinine clearance in rats with NO synthase inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: